Iberiabank Corp lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,754 shares of the medical research company’s stock after selling 480 shares during the quarter. Iberiabank Corp’s holdings in Amgen were worth $3,783,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen in the 3rd quarter worth approximately $108,000. Phocas Financial Corp. purchased a new position in shares of Amgen in the 2nd quarter worth approximately $110,000. Jackson Grant Investment Advisers Inc. grew its position in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the last quarter. Omnia Family Wealth LLC grew its position in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after buying an additional 147 shares during the last quarter. Finally, Horan Capital Advisors LLC. purchased a new position in shares of Amgen in the 3rd quarter worth approximately $150,000. Institutional investors and hedge funds own 79.61% of the company’s stock.
A number of research analysts have recently issued reports on AMGN shares. Cann reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research report on Thursday, November 30th. Oppenheimer reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research report on Thursday, November 30th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Goldman Sachs Group downgraded shares of Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Finally, Citigroup downgraded shares of Amgen to a “neutral” rating in a research report on Monday, December 18th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. Amgen has an average rating of “Hold” and an average price target of $191.72.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s revenue was down 2.7% on a year-over-year basis. During the same period last year, the company earned $2.89 earnings per share. sell-side analysts predict that Amgen, Inc. will post 13.24 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be issued a $1.32 dividend. This represents a $5.28 annualized dividend and a dividend yield of 2.78%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is currently 205.45%.
Amgen announced that its board has approved a stock repurchase plan on Thursday, February 1st that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.19% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/iberiabank-corp-sells-480-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.